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Purpose
Letrozole showed efficacy and generally favorable toxicities, along with the convenience of
oral administration in postmenopausal patients with hormone receptor (HR)–positive
metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports
of the clinical outcomes in Korean patients, although letrozole is widely used in practice.
Therefore, this study was conducted to affirm the efficacy and toxicities of letrozole in Korean
patients.
Materials and Methods
This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with
letrozole from January 2001 to December 2012. Clinicopathological characteristics and
treatment history were extracted from medical records. All patients received 2.5 mg letrozole
once a day until there were disease progressions or unacceptable toxicity. Progression-free
survival (PFS) was the primary endpoint, and secondary endpoints were overall survival
(OS), objective response rate (ORR), and toxicity.
Results
The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median
PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4
months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable
lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437;
95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval  2 years (hazard ratio, 2.697;
95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. How-
ever, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was gen-
erally well tolerated.
Conclusion
Letrozole showed considerable efficacy and tolerability as a first-line treatment in post-
menopausal patients with HR-positive MBC.
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Introduction
Breast cancer is the second most common cancer world-
wide, with more than one million new cancer cases annually
[1]. Breast cancer is also a major cancer in Korea [2]. Metasta-
tic breast cancer (MBC) accounts for 20%-30% of all breast
cancer cases and remains incurable; therefore, systemic ther-
apy plays an essential role in the treatment of MBC. Among
systemic therapies, endocrine therapy (ET) is the mainstay
of treatment for patients with hormone receptor (HR)–posi-
tive MBC. Because ET is as effective as chemotherapy but less
toxic, it should be recommended first in patients with HR-
positive MBC except in cases of rapidly progressive disease
[3]. 
Aromatase inhibitors (AIs) are commonly used in practice
in adjuvant and palliative settings. AIs inhibit the aromatase
enzyme, resulting in interruption of estrogen synthesis and
suppression of tumor growth [4-7]. Currently, there are three
clinically available third-generation AIs; two reversible non-
steroidal AIs, letrozole and anastrozole; and one irreversible
steroidal AI, exemestane. All three agents are at least as 
effective as tamoxifen in postmenopausal patients with HR-
positive MBC [4-6]. A randomized phase III clinical trial to
compare letrozole with tamoxifen as first-line treatment
showed that letrozole was superior to tamoxifen in terms of
objective response rate (ORR), time to progression, and over-
all survival (OS) [6]. However, the majority of trials for AIs
were conducted in Western patients. For this reason, there
has been no satisfactory clinical data describing letrozole,
particularly in Korean patients. Therefore, we investigated
the efficacy and toxicity of letrozole as a first-line treatment
for postmenopausal patients with HR-positive MBC.
Materials and Methods
1. Study population
We searched all patients who received letrozole as a pal-
liative treatment regardless of ordinal lines of therapy 
between January 2001 and December 2012 (Fig. 1). A total of
407 patients met these criteria. Among the 407 patients, 230
who received prior chemotherapy and 90 treated with a sec-
ond or further lines of treatment were excluded from our
analysis. Menopause was defined as follows: prior bilateral
oophorectomy, age > 60 years, age < 60 years with amenor-
rhea for 12 or more months in the absence of chemotherapy,
tamoxifen, toremifene, ovarian suppression, or follicle-stim-
ulating hormone/estradiol in the postmenopausal range [7].
This protocol was reviewed and approved by the Institu-
tional Review Board of Seoul National University Hospital
(SNUH) (IRB No. 1411-038-624). The recommendations of the
Declaration of Helsinki were also observed.
Metastatic breast cancer patients treated 
  with letrozole monotherapy at SNUH
  From January 2001 through December 2012 (n=407)
Palliative letrozole treatment (n=177)
Treated at 2nd or more line (n=90)
A total of analyzed patients (n=84)
Patients received letrozole treatment 
  at 1st line (n=87)
Maintenance letrozole after 
  cytotoxic chemotherapy (n=230)
Follow-up loss before 
  response evaluation (n=3)
Fig. 1.  CONSORT diagram of patients included in analysis. SNUH, Seoul National University Hospital.
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2. Data collection
We reviewed the medical records of all patients for the fol-
lowing characteristics: age, disease status, HR status, human
epidermal growth factor receptor 2 (HER-2) status, Ki-67 sta-
tus, adjuvant treatments, date of recurrence, cancer antigen
15-3 level, number of metastatic organs, and dominant
metastatic site. estrogen receptor (ER) or progesterone recep-
tor (PR) positivity was defined as staining for ER or PR 
 1% of tumor cells by immunohistochemistry (IHC). HER-2
positivity was defined as an IHC of 3+ or 2+ and HER-2 flu-
orescence in situ hybridization–positive. The high level of 
Ki-67 was defined as an IHC of Ki-67  14% of tumor cells
[8]. The treatment response was evaluated according to the
Response Evaluation Criteria in Solid Tumors ver. 1.1. The
grading of toxicity was recorded according to the National
Cancer Institute Common Toxicity Criteria for Adverse
Events (NCI-CTCAE) ver. 4.0. ET-sensitive was defined as a
relapse after  1 year of completion of adjuvant ET. Disease-
free interval (DFI) was calculated from the day of curative
resection to the date of tumor recurrence. Progression-free
survival (PFS) was measured from the first day of letrozole
treatment until tumor progressions or death of any cause. OS
was calculated from the first day of letrozole treatment to 
patient death or the last date of follow-up. ORR was defined
as the proportion of patients with either a complete response
or a partial response. The clinical benefit rate (CBR) was 
defined as the proportion of patients achieving the best over-
all response of complete response, partial response, or stable
disease lasting for at least 6 months.
3. Treatment and follow-up
All patients received 2.5 mg letrozole once a day until dis-
ease progression or withdrawal due to toxicity or patient’s
decision. Tumor response was evaluated using the appropri-
ate imaging modalities at least every 2 months in the first 6
months and every 3 months thereafter, or whenever there
was clinical evidence of disease progression.
4. Statistical analysis
Categorical variables were compared with the Pearson’s
chi-square test or Fisher exact test, as appropriate. PFS and
OS were calculated using the Kaplan-Meier method. The log-
rank test was used to compare the probability of survival 
between subgroups. Multivariate analysis was performed
using the Cox proportional hazards model, and hazard ratios
were calculated using a 95% confidence interval. Two-sided
p-values of < 0.05 were considered significant. All analyses
were conducted using the PASW ver. 18.0 software package
(SPSS Inc., Chicago, IL).
Results
1. Clinicopathological characteristics
A total of 84 patients with measurable disease were 
included in our study. Baseline characteristics of the entire
study population are summarized in Table 1. The mean age
at diagnosis of the metastatic or recurrent disease was
59.3±10.5 years (median, 59.3 years; range, 36.4 to 85.7 years).
Overall, 54 patients (64.3%) had both ER- and PR-positive
tumor, while 27 (32.1%) and three (3.6%) had ER-positive
/PR-negative tumor and ER-negative/PR-positive tumor, 
respectively. Seven patients (8.3%) had HER2-positive breast
cancer. Among 46 patients in whom Ki-67 could be deter-
mined, 10 (11.9%) had a high level of Ki-67. Moreover, 34 
patients (40.5%) had bone-dominant metastasis and 21 
patients (25.0%) had lymph node or soft tissue metastasis.
Among 48 patients who received adjuvant tamoxifen, 
14 (29.2%) had ET-sensitive tumors.
2. Prior treatment
A total of 74 patients (88.1%) underwent curative surgery.
Adjuvant ET data were insufficient for 26 patients; therefore,
only 48 (64.9%) received tamoxifen as an adjuvant ET. More-
over, only three patients received anastrozole following 
tamoxifen as sequential treatment, while 58 (78.4%) received
adjuvant chemotherapy. Additionally, 60 patients (81.1%)
had a DFI > 2 years, and 14 patients (29.2%) were ET-sensi-
tive in the adjuvant ET group. The median DFI in ET-sensi-
tive patients was 8.95 years (range, 6.25 to 18.3 years), while
the median PFS and median OS were longer in the ET 
responsive group than the non-responsive group; however,
these differences were not statistically significant (median
PFS, 12.3 vs. 34.1 months; p=0.266; median OS, 52.6 vs. 74.0
months; p=0.262; log-rank test). 
3. The efficacy and survival analysis of letrozole
The median follow-up was 71 months, and the median 
duration of treatment was 17.1 months. The most common
reasons for discontinuing letrozole were disease progression
(97.6%), followed by drug toxicity (arthralgia grade 3, 2.4%).
The ORR and CBR were 36.9% and 82.1%, respectively 
(Table 2). Median PFS and OS were 16.8 months (95% confi-
dence interval [CI], 9.8 to 23.8) and 56.4 months (95% CI, 38.1
to 74.7), respectively (Fig. 2). Shorter PFS and OS were seen
in patients with a DFI  2 years or initial metastasis or symp-
tomatic visceral disease (Fig. 3).
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4. The univariate and multivariate analysis
Subgroup analysis revealed that the ORR for patients with
a DFI > 2 years was significantly higher than that of patients
with a DFI  2 years (43.3% vs. 14.3%, p=0.044) (Table 3). Uni-
variate analysis revealed that short DFI ( 2 years), initial
metastasis and symptomatic visceral metastasis were signif-
icantly associated with short PFS (Table 4). However, ET-
responsiveness did not affect PFS. Upon multivariate analy-
sis, short DFI ( 2 years), initial metastasis and symptomatic
visceral metastasis also significantly influenced PFS (Table 4).
Table 2. The best treatment responses to first-line letro-
zole




Objective response ratea) 31/84 (36.9)
Clinical benefit rateb) 69/84 (82.1)
CR, complete response; PR, partial response; SD, stable dis-
ease; PD, progressive disease. a)Defined as proportion of
patients having the best overall response of either CR or
PR, b)Defined as the proportion of patients having the best
overall response of CR, PR, or SD for at least 6 months. 
Table 1. Continued
Characteristic No. of patients (%)
No. of metastatic organs (n=84)
1 13 (15.5)
 2 71 (84.5)
Dominant metastatic site (n=84)
Bone 34 (40.5)
Lymph node or soft tissue 21 (25.0)
Asymptomatic visceral metastasis 13 (15.5)
Symptomatic visceral metastasis 16 (19.0)
ER, estrogen receptor; PR, progesterone receptor; HER2,
human epidermal growth factor receptor 2; CMF, cyclo-
phosphamide+methotrexate+5-fluorouracil; ET, endocrine
treatment; CA 15-3, cancer antigen 15-3; IHC, immunohis-
tochemistry. a) 1% cells were positive for hormone recep-
tor as assessed by IHC staining, b)IHC score 3+ or une-
quivocal amplification as assessed by fluorescence in situ
hybridization were positive for HER-2 status, c) 14% cells
were high for Ki-67 as assessed by IHC. 
Table 1. Clinicopathologic characteristics of patients
Characteristic No. of patients (%)
Total  84
Age, mean (range, yr) 59.3 (36.4-85.7)           
< 55 29 (34.5)
 55 55 (65.5)
Disease status 
Relapsed disease 74 (88.1)
Initially metastatic disease 10 (11.9)
Hormonal receptor statusa)
ER+, PR+ 54 (64.3)
ER+, PR– 27 (32.1)






















Adjuvant hormone treatment (n=74)
Unknown 26 (35.1)
Yes 48 (64.9)
Tamoxifen alone 45 




Disease-free interval (yr) (n=74)
 2 14 (18.9)
> 2 60 (81.1)
CA 15-3 level (U/mL) (n=84)
 30 54 (64.3)
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5. Toxicity
The observed toxicity in our study was limited, with most
adverse events being mild to moderate. Only two patients
discontinued letrozole due to general weakness and arthral-
gia. Evaluation of bone health was available for 31 patients.
Only one patient (3.2%) had a left proximal humerus fracture
related to osteoporosis, while two (6.4%) had newly detected
osteoporosis while using letrozole as defined by the NCI-
CTCAE ver. 4.0.
Discussion
Upon meta-analysis [3], AIs showed similar efficacy and
less toxicity than chemotherapy. The phase III trials [5,6,9]
demonstrated that anastrozole or letrozole was superior to
tamoxifen as a first-line treatment in postmenopausal 
patients with MBC. Based on both meta-analysis and phase
III trials, anastrozole or letrozole is the standard first-line
therapy in postmenopausal patients with HR-positive MBC.
However, most AI trials in MBC have been tested in Western
patients, not Asian patients, and there have not been any
data relevant to AIs generated in HR-positive MBC to date,
particularly in Korean patients. Moreover, only 40% of 
Korean patients with breast cancer are postmenopausal [10],
which seems to be lower than in Western countries. As a 
result, it is not easy to perform a large-scaled study for AIs,
particularly in Korean postmenopausal patients. To the best
of our knowledge, even though this is a retrospective analy-
sis, our study has the largest scale of analysis for letrozole as
a first-line treatment in Korean postmenopausal patients
with HR-positive MBC.
In our study, PFS, OS, and ORR were 16.8 months, 56.4
months, and 36.9%, respectively, which is more favorable
than in other studies. Moreover, short DFI and symptomatic
visceral metastasis were significantly related to poorer clini-
cal outcomes (Table 4, Fig. 3). Unfortunately, we found no
DFI data in phase III trials of and therefore could not com-
pare them with our study directly. It is important to point
out that even in the PO25 study [11], only the median DFI
(5.9 years) was given. In our study, categorization of DFI was
based on two years and the median DFI was 6.1 years (range,
0.1 to 37.4 years). Moreover, it is difficult to compare these
values directly, because no previous studies divided patients
into symptomatic and asymptomatic visceral metastasis.
Rather, most studies conducted to date have used nonvis-
ceral and visceral metastases to separate the dominant metas-
tasis. Particularly, in visceral metastasis, only liver invol-
vement was considered, not the symptoms. Therefore, our
study is unique in that it confirms symptoms as an important
factor.
A randomized phase III (PO25) trial to compare letrozole
with tamoxifen in postmenopausal patients with MBC
showed better clinical benefits in letrozole [6,11]. ORR 
appeared to be similar between our study and the PO25
study. However, PFS and OS in our study were better than
in other trials, including the PO25 study. This result may
have occurred because the proportion of patients with initial
metastasis at diagnosis was much lower than in other phase
III studies (Table 5), and most enrolled subjects were recur-
rent cases (88.1%) in the present study. The disease burden
of recurrent cases may have been smaller at the time of diag-
nosis since it was detected early through routine regular fol-
low-up examination. The rate of dominant visceral meta-
stasis was greater in the PO25 study (43%) than in our study
(34.6%). Moreover, there were fewer patients with relatively
adverse dominant metastatic sites such as liver involvement
in this study (Table 5). In addition, one prior chemotherapy
regimen for the treatment of metastatic disease was permit-
ted in the PO25 trial, whereas our patients received letrozole
treatment as their first-line therapy in the metastatic setting.
It is also possible that the patients who were selected to be
treated with first-line ET instead of chemotherapy had a
tumor with a more indolent nature. Therefore, our results
may show better survival than those of previous studies.
Even in the group with visceral metastasis, patients with
no symptoms had a median PFS four times longer (40.6















10 20 5040 60 70 80 90 110100 130120 14030
0
Median PFS, 16.8 mo
Median OS, 56.4 mo
Fig. 2. Progression-free survival (PFS) and overall survival
(OS) of first-line letrozole treatment.
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(89.5 months vs. 24.2 months) than those with symptoms
(Fig. 3). Moreover, patients with a DFI  2 years or initial
metastatic diseases also showed shorter survival than those
without. Cytotoxic chemotherapy may be preferred for 
patients of a relatively young age, with short DFI, with initial
metastasis or in need of rapid symptom control. Therefore,
any of the third generation AIs may be used for front-line
treatment of HR-positive MBC in postmenopausal patients
without visceral crisis [12,13]. Treatment decisions are based
on symptoms and disease severity (e.g., impending visceral
crisis), DFI, patient age, performance status, sites of disease
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Fig. 3. Progression-free survival (PFS) (A) and overall survival (OS) (B) based on disease-free interval (DFI). Median PFS for
initial metastasis, DFI  2 years and DFI > 2 years: 9.3 months vs. 11.2 months vs. 22.8 months, p=0.004, log-rank test; median
OS: 32.4 months vs. 44.9 months vs. 74.0 months, p=0.001, log-rank test. PFS (C) and OS (D) based on subgroups of dominant
metastatic sites. Median PFS for bone, lymph nodes (LNs) or soft tissues, asymptomatic visceral metastasis, and symptomatic
visceral metastasis: 18.5 months vs. 17.8 months vs. 40.6 vs. 8.8 months, p=0.002, log-rank test; median OS: 67.8 months vs.
56.4 months vs. 89.5 vs. 24.2 months, p=0.004, log-rank test.
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preferences, maintaining or improving quality of life, and
minimizing treatment toxicities. Even if patients had symp-
toms or metastatic diseases initially, an anti-hormone ther-
apy would be useful when tumor tissues were revealed as
strongly ER positive or it is difficult to proceed with
chemotherapy because of old age. In our study, although 
patients had the above risk factors, they were treated with
ET if they were elderly, had lower Eastern Cooperative 
Oncology Group performance scores, or did not want
chemotherapy. To date, there has been no evidence of con-
current cytotoxic chemotherapy and cytostatic ET resulting
in improved survival among advanced breast cancer 
patients. Therefore, we recommend ET and chemotherapy
be performed sequentially to fit individual patients’ situa-
tions.
Endocrine resistance is a critical issue for patients with HR-
positive MBC. Some tumors harbor intrinsic resistances to
endocrine agents, and in the metastatic setting, all tumors 
ultimately acquire resistance to ET. In this study, there were
no statistically significant differences in treatment response
and survival between patients who had recurred after  1
year of completion of adjuvant ET and those who had not.
Patients with previous ET (tamoxifen) were included in the
Phase III trials shown in Table 5, and third generation AIs
drew favorable clinical outcomes. Moreover, the past tamox-
ifen treatment history did not affect the AI effect in any of
the studies summarized in Table 5. There are different resist-
ance mechanisms of tamoxifen and letrozole in genome-wide
Table 3. Treatment responses in patient subgroups
Prognostic factor Objective p-valuea) Clinical p-valuea)response benefit
Age (yr) (n=84)
< 55 8/29 (27.6) 0.199 23/29 (79.3) 0.623
 55 23/55 (41.8) 46/55 (83.6)
Hormone receptor statusb) (n=84)
Both receptors positive 20/54 (37.0) 0.973 44/54 (81.5) 0.832
Only one receptor positive 11/30 (36.7) 25/30 (83.3)
HER-2 statusc) (n=84)
Negative 15/51 (29.4) 0.098 42/51 (82.4) 0.720
Positive 2/7 (28.6) 5/7 (71.4)
Undetermined 14/26 (53.8) 22/26 (84.6)
Ki-67 statusd) (n=84)
Low 10/36 (27.8) 0.194 30/36 (83.3) 0.964
High 3/10 (30.0) 8/10 (80.0)
Undetermined 18/38 (47.4) 31/38 (81.6)
Disease status (n=74)
Disease-free interval  2 yr 2/14 (14.3) 0.044 11/14 (78.6) 0.702
Disease-free interval > 2 yr 26/60 (43.3) 50/60 (83.3)
No. of metastatic organs (n=84)
1 3/13 (23.1) 0.355 11/13 (84.6) 1.000
 2 28/71 (39.4) 58/71 (81.7)
Dominant metastatic site (n=84)
Bone 9/34 (26.5) 0.217 29/34 (85.3) 0.136
Lymph node or soft tissue 11/21 (52.4) 18/21 (85.7)
Asymptomatic visceral metastasis 6/13 (46.2) 12/13 (92.3)
Symptomatic visceral metastasis 5/16 (31.3) 10/16 (62.5)
ET-responsiveness (n=48)
No 11/34 (32.4) 0.251 27/34 (79.4) 0.407
Sensitive 7/14 (50.0) 13/14 (92.9)
Values  are presented as number (%). HER-2, human epidermal growth factor receptor 2; ET, endocrine treatment; IHC, 
immunohistochemistry. a)Chi-square test, b) 1% cells were positive for hormone receptors as assessed by IHC staining, c)IHC
score 3+ or unequivocal amplification as assessed by fluorescence in situ hybridization were positive for HER-2 status, d) 14%
cells were high for Ki-67 as assessed by IHC.
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analysis [14]; therefore, these findings suggest that there no
cross-resistance between these mechanisms. However, the
mechanisms underlying resistance to ET are complex [15].
Recent studies of PALOMA-1 [16], and Turner et al. [17]
demonstrated that endocrine monotherapy had limited effi-
cacy in patients with disease progression after previous 
exposure to ET, irrespective of clinically or molecularly 
defined endocrine sensitivity, suggesting a need for the rou-
tine use of more effective combination regimens. In our
study, the clinical outcomes with no statistically significant
difference according to ET-responsiveness might have 
occurred because of the relatively small sample sizes. There-
fore, further studies and validation are warranted.
It should be noted that our study had the following limi-
tations. First, the retrospective design made it difficult to
compare functional status, symptoms, and toxicity profiles
among patients. Second, the enrolled patients were selected
from a single institution in Korea, and the relatively small
sample size may limit the statistical power to derive signifi-
cant outcomes and correct the differences in subgroup char-
acteristics. Despite these limitations, our analysis investi-
gated a homogeneous patient population with a large case
series of postmenopausal women treated with the first line




HR (95% CI) p-valuea) HR (95% CI) p-valuea)
Age (yr) (n=84)
< 55 1 ( 0.782 1 ( 0.793
 55 1.073 (0.652-1.765) 1.085 (0.590-1.998)
Hormone receptor statusb) (n=84)
Both receptors positive 1 ( 0.798 1 ( 0.375
One receptor positive only 1.067 (0.649-1.753) 1.285 (0.738-2.240)
HER-2 statusc) (n=84)
Negative 1 ( 0.291 1 ( 0.642
Positive 1.134 (0.664-1.936) 0.644 0.709 (0.279-1.804) 0.471
Undetermined 1.977 (0.829-4.716) 0.124 0.790 (0.437-1.426) 0.434
Ki-67 statusd) (n=84)
Low 1 ( 0.401 1 ( 0.341
High 1.474 (0.709-3.065) 0.299 1.964 (0.735-5.247) 0.178
Undetermined 0.903 (0.540-1.512) 0.699 1.457 (0.784-2.708) 0.234
Disease status (n=84)
Disease-free interval > 2 yr     1 ( 0.004 1 ( 0.009
Disease-free interval  2 yr 2.051 (1.095-3.840) 0.025 2.697 (1.262-5.762) 0.010
Initially metastatic disease 2.907 (1.376-6.140) 0.005 2.519 (1.113-5.703) 0.027
No. of metastatic organs (n=84)
1 1 ( 0.174 1 ( 0.230
 2 1.675 (0.797-3.523) 1.635 (0.733-3.646)
Dominant metastatic site (n=84)
Bone 1 ( 0.002 1 ( 0.004
Lymph node or soft tissue 1.380 (0.756-2.519) 0.294 1.122 (0.552-2.282) 0.750
Asymptomatic visceral metastasis 0.813 (0.389-1.696) 0.581 0.721 (0.331-1.572) 0.411
Symptomatic visceral metastasis 3.077 (1.584-5.975) 0.001 3.437 (1.576-7.495) 0.002
ET-responsiveness (n=48)
No 1 ( 0.252 1 ( 0.455
Sensitive 0.680 (0.351-1.317) 0.749 (0.352-1.597)
Table 4. Univariate and multivariate analyses of predictive factors for progression-free survival  
HR, hazard ratio; CI, confidence interval; HER-2, human epidermal growth factor receptor 2; ET, endocrine treatment; IHC,
immunohistochemistry. a)Cox proportional hazard model,  b) 1% cells were positive for hormone receptor as assessed by
IHC staining, c)IHC score 3+ or unequivocal amplification as assessed by fluorescence in situ hybridization were positive for
HER-2 status, d) 14% cells were high for Ki-67 as assessed by IHC. 
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Conclusion
Letrozole showed good efficacy and tolerability in Korean
postmenopausal patients. However, the characteristics of 
Korean patients differ from those of Western patients in
terms of age, menopausal status and disease status at first 
diagnosis. Therefore, a prospective clinical trial to reveal the
efficacy and toxicity of AIs in Korean patients is warranted. 
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Table 5. Phase III trials using AIs as first-line treatment in postmenopausal patients with MBC
Bonneterre Nabholtz Mouridsen Our studyet al. [5] et al. [9] et al. [6,18]
Design Phase III Phase III Phase III Retrospective 
analysis
Population Europe, USA, Europe, Korea
Australia, Canada North America,
New Zealand, South America,
South America, South Africa,
South Africa India, Egypt, Israel
Investigating agent Anastrozole Anastrozole Letrozole Letrozole 
(n=340) (n=171) (n=453) (n=84)
Age, mean (range, yr) 67 (34-91) 68 ( 65 (31-96) 59 (36-86)
Disease status at first diagnosis
Initial metastasis (%) 48 ( 30 ( 32 ( 12 (
Relapse (%) 52 ( 69 ( 68 ( 88 (
Overall response rate (%) 32.9 ( 21 ( 32 ( 37 (
Median time to progression (mo) 8.2 ( 11.1 ( 9.4 ( 16.8 (
Nonvisceral metastasis, n (%) 237 (69.7) 88 (51.5) 258 (57) 55 (65.5)
Median TTP (mo) - - 10.9 ( 18.1 (
Viscera metastasis without liver involvement, n (%) 71 (20.9) 70 (40.9) 135 (29.8) 26 (31)
Median TTP (mo) - - 11.9 ( 16.8 (
Viscera metastasis with liver involvement, n (%) 32 (9.4) 13 (7.6) 60 (13.2) 3 (3.6)
Median TTP (mo) - - 3.8 ( 10.0 (
AI, aromatase inhibitor; MBC, metastatic breast cancer.
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